Medical Therapy of Hepatobiliary Diseases Associated with Ulcerative Colitis

Author(s):  
Chalermrat Bunchorntavakul ◽  
K. Rajender Reddy
2021 ◽  
Author(s):  
Burton I Korelitz ◽  
Judy Schneider

Abstract We present a bird’s eye view of the prognosis for both ulcerative colitis and Crohn’s disease as contained in the database of an Inflammatory Bowel Disease gastroenterologist covering the period from 1950 until the present utilizing the variables of medical therapy, surgical intervention, complications and deaths by decades.


2011 ◽  
Vol 64 (10) ◽  
pp. 817-824
Author(s):  
Naoki Yoshimura ◽  
Masakazu Takazoe

The Lancet ◽  
1993 ◽  
Vol 342 (8868) ◽  
pp. 412-417 ◽  
Author(s):  
StephenB Hanauer

1966 ◽  
Vol 1 (1) ◽  
pp. 26-27
Author(s):  
Y. Nao ◽  
Y. Murakami ◽  
H. Maki ◽  
H. Obata ◽  
A. Kobayashi ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
pp. 94 ◽  
Author(s):  
Maia Kayal ◽  
Shailja Shah

Historically, medical therapy for ulcerative colitis (UC) was limited to corticosteroids. Excitingly, over the past just 1–2 decades, the options for medical therapy have expanded and include biologics and small molecules, with more agents actively being developed. In this article, we review the current and emerging treatment strategies for UC stratified according to disease severity.


2015 ◽  
Vol 163 (4) ◽  
pp. 262 ◽  
Author(s):  
Meenakshi Bewtra ◽  
Craig W. Newcomb ◽  
Qufei Wu ◽  
Lang Chen ◽  
Fenglong Xie ◽  
...  

2002 ◽  
Vol 31 (1) ◽  
pp. 147-166 ◽  
Author(s):  
Niraj Jani ◽  
Miguel D Regueiro

Sign in / Sign up

Export Citation Format

Share Document